Fulcrum Therapeutics, Inc. Common Stock
FULC
FULC: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.
moreShow FULC Financials
Recent trades of FULC by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by FULC's directors and management
Government lobbying spending instances
-
$30,000 Jul 19, 2023 Issue: Health Issues
-
$30,000 Apr 20, 2023 Issue: Health Issues
-
$30,000 Jan 19, 2023 Issue: Health Issues
-
$20,000 Oct 18, 2022 Issue: None
New patents grants
-
Patent Title: Macrocyclic azolopyridine derivatives as eed and prc2 modulators Feb. 28, 2023
-
Patent Title: Use of p38 inhibitors to reduce expression of dux4 Oct. 25, 2022
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Apr. 05, 2022
-
Patent Title: Macrocyclic azolopyridine derivatives as eed and prc2 modulators Apr. 13, 2021
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Jan. 21, 2020
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Jul. 09, 2019
Federal grants, loans, and purchases
Followers on FULC's company Twitter account
Number of mentions of FULC in WallStreetBets Daily Discussion
Recent insights relating to FULC
Recent picks made for FULC stock on CNBC
ETFs with the largest estimated holdings in FULC
Flights by private jets registered to FULC